- Home
- ETON vs ALT Comparison
ETON vs ALT Comparison
Compare ETON & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | ALT |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.9M | 415.3M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ETON | ALT |
|---|---|---|
| Price | $16.80 | $3.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $31.00 | $16.00 |
| AVG Volume (30 Days) | 298.4K | ★ 2.8M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,011,000.00 | $41,000.00 |
| Revenue This Year | $107.23 | N/A |
| Revenue Next Year | $29.72 | $756,308.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 23.29 | ★ 105.00 |
| 52 Week Low | $11.09 | $2.91 |
| 52 Week High | $23.00 | $7.73 |
Technical Indicators
Market Signals| Indicator | ETON | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 30.87 |
| Support Level | $16.04 | $3.39 |
| Resistance Level | $17.59 | $4.25 |
| Average True Range (ATR) | 1.05 | 0.24 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 6.21 | 13.55 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.